CN109761976B - 八氢稠合的氮杂萘烷糖皮质激素受体调节剂 - Google Patents

八氢稠合的氮杂萘烷糖皮质激素受体调节剂 Download PDF

Info

Publication number
CN109761976B
CN109761976B CN201910143177.XA CN201910143177A CN109761976B CN 109761976 B CN109761976 B CN 109761976B CN 201910143177 A CN201910143177 A CN 201910143177A CN 109761976 B CN109761976 B CN 109761976B
Authority
CN
China
Prior art keywords
compound
pyrazolo
ring
fluorophenyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910143177.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109761976A (zh
Inventor
H·亨特
I·瓦尔特斯
B·古尔迪特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CN109761976A publication Critical patent/CN109761976A/zh
Application granted granted Critical
Publication of CN109761976B publication Critical patent/CN109761976B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201910143177.XA 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂 Active CN109761976B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361908333P 2013-11-25 2013-11-25
US61/908,333 2013-11-25
US201461985035P 2014-04-28 2014-04-28
US61/985,035 2014-04-28
CN201480074087.5A CN106029066B (zh) 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480074087.5A Division CN106029066B (zh) 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂

Publications (2)

Publication Number Publication Date
CN109761976A CN109761976A (zh) 2019-05-17
CN109761976B true CN109761976B (zh) 2021-11-23

Family

ID=53180165

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910143177.XA Active CN109761976B (zh) 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
CN201480074087.5A Active CN106029066B (zh) 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480074087.5A Active CN106029066B (zh) 2013-11-25 2014-11-21 八氢稠合的氮杂萘烷糖皮质激素受体调节剂

Country Status (20)

Country Link
US (8) US10047082B2 (enExample)
EP (4) EP3848027B1 (enExample)
JP (6) JP6516743B2 (enExample)
KR (1) KR102352737B1 (enExample)
CN (2) CN109761976B (enExample)
AU (1) AU2014352915B2 (enExample)
BR (1) BR112016011826B1 (enExample)
CA (1) CA2931302C (enExample)
DK (2) DK3848027T3 (enExample)
ES (3) ES2943542T3 (enExample)
FI (1) FI3848027T3 (enExample)
IL (1) IL245848B (enExample)
MX (1) MX368167B (enExample)
MY (1) MY180141A (enExample)
PH (1) PH12016500968B1 (enExample)
PL (3) PL3560493T3 (enExample)
PT (2) PT3848027T (enExample)
RU (1) RU2674983C1 (enExample)
WO (1) WO2015077530A1 (enExample)
ZA (1) ZA201604026B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
RU2674983C1 (ru) * 2013-11-25 2018-12-14 Корсепт Терапеутикс, Инк. Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
KR102845317B1 (ko) 2016-03-01 2025-08-13 코어셉트 쎄라퓨틱스 인코포레이티드 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
CN106478464B (zh) * 2016-08-30 2018-06-05 黄河三角洲京博化工研究院有限公司 一种2-氟-6-三氟甲基苯磺酰氯的制备方法
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
AU2018230429B2 (en) 2017-03-09 2023-06-15 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
KR102342620B1 (ko) 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
US20180325891A1 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CA3098118C (en) 2018-04-23 2023-09-05 Corcept Therapeutics, Inc. Methods of preparing regioselective n-alkyl triazoles
TWI811400B (zh) * 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
SG11202105770YA (en) 2018-12-19 2021-07-29 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP4045045A4 (en) 2019-10-16 2023-11-22 Corcept Therapeutics Incorporated METHOD FOR NORMALIZING THE RATIO BETWEEN NEUTROPHILS AND LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST
EP4072556A4 (en) 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated METHODS OF TREATING ANTIPSYCHOTIC DRUG-INDUCED WEIGHT GAIN WITH MIRICORILANT
EP4076470B1 (en) 2019-12-21 2025-12-03 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
PH12022551938A1 (en) 2020-01-29 2023-10-23 Corcept Therapeutics Inc TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
KR20220140567A (ko) * 2020-02-10 2022-10-18 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 조절제를 사용하여 항-종양 반응을 자극하는 방법
KR20230027245A (ko) 2020-06-22 2023-02-27 코어셉트 쎄라퓨틱스 인코포레이티드 4차 인다졸 글루코코르티코이드 수용체 길항제
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
AU2022417485A1 (en) 2021-12-21 2024-07-04 Corcept Therapeutics Incorporated Piperazine indazole glucocorticoid receptor antagonists
CA3243547A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Inc INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS
CN119997939A (zh) 2022-10-06 2025-05-13 科赛普特治疗公司 糖皮质激素受体调节剂的制剂
CN120202004A (zh) 2022-10-28 2025-06-24 科赛普特治疗学股份有限公司 使用达祖可兰治疗肌萎缩侧索硬化症
AU2024223250A1 (en) * 2023-02-17 2025-08-14 Corcept Therapeutics Incorporated Methods and compositions for treating huntington's disease and its symptoms
US20240390341A1 (en) * 2023-05-22 2024-11-28 Corcept Therapeutics Incorporated Methods for treating adrenal gland tumors
WO2025152964A1 (en) * 2024-01-15 2025-07-24 Insilico Medicine Ip Limited Novel compounds as glucocorticoid receptor modulators and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963558A (en) * 1988-12-08 1990-10-16 Lilly Industries Limited Pyrazolo-[3,4-g]isoquinoline derivatives useful to treat CNS disorders
CN101027301A (zh) * 2004-03-09 2007-08-29 科塞普特治疗公司 稠环氮杂十氢化萘糖皮质激素受体调节剂
CN101155783A (zh) * 2005-04-05 2008-04-02 霍夫曼-拉罗奇有限公司 吡唑类
CN101910171A (zh) * 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
CN103080108A (zh) * 2010-08-27 2013-05-01 科赛普特治疗公司 吡啶基-胺稠合的氮杂萘烷调节剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (enExample) 1954-11-30 1957-04-11
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
CA1270488A (en) 1983-09-26 1990-06-19 John M. Schaus Pyrazole-ring alkylated pyrazoloquinolines and intermediates
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
AU690576B2 (en) 1993-08-06 1998-04-30 Smithkline Beecham Spa Hydroisoquinoline derivatives
CA2683097A1 (en) 1998-03-10 1999-09-16 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
JP2004512358A (ja) * 2000-11-02 2004-04-22 アクゾ・ノベル・エヌ・ベー 高コルチゾール血症関連の障害を治療するためのコルチゾール封鎖剤の使用
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
EP1408981B1 (en) * 2001-07-23 2008-08-27 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
US6679935B2 (en) * 2001-08-14 2004-01-20 Apex Advanced Technologies, Llc Lubricant system for use in powdered metals
EP1467730A4 (en) 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
WO2005070893A2 (en) 2004-01-09 2005-08-04 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2009100171A1 (en) * 2008-02-07 2009-08-13 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
JP2014501785A (ja) 2011-01-07 2014-01-23 コーセプト セラピューティクス， インコーポレイテッド ステロイドおよびグルココルチコイド受容体アンタゴニスト組合せ治療
US20130225633A1 (en) 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP6172871B2 (ja) 2012-05-25 2017-08-02 コーセプト セラピューティクス， インコーポレイテッド ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子
RU2674983C1 (ru) 2013-11-25 2018-12-14 Корсепт Терапеутикс, Инк. Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963558A (en) * 1988-12-08 1990-10-16 Lilly Industries Limited Pyrazolo-[3,4-g]isoquinoline derivatives useful to treat CNS disorders
CN101027301A (zh) * 2004-03-09 2007-08-29 科塞普特治疗公司 稠环氮杂十氢化萘糖皮质激素受体调节剂
CN101155783A (zh) * 2005-04-05 2008-04-02 霍夫曼-拉罗奇有限公司 吡唑类
CN101910171A (zh) * 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
CN103080108A (zh) * 2010-08-27 2013-05-01 科赛普特治疗公司 吡啶基-胺稠合的氮杂萘烷调节剂

Also Published As

Publication number Publication date
US12139486B2 (en) 2024-11-12
JP2018012734A (ja) 2018-01-25
EP3848027B1 (en) 2023-04-05
PT3848027T (pt) 2023-05-11
JP2016537394A (ja) 2016-12-01
IL245848B (en) 2020-08-31
EP3560493B1 (en) 2021-03-31
WO2015077530A1 (en) 2015-05-28
US20210139478A1 (en) 2021-05-13
EP3074011A1 (en) 2016-10-05
ES2743620T3 (es) 2020-02-20
PH12016500968A1 (en) 2016-07-18
US20190241563A1 (en) 2019-08-08
CA2931302A1 (en) 2015-05-28
CN106029066B (zh) 2019-03-15
IL245848A0 (en) 2016-07-31
RU2674983C1 (ru) 2018-12-14
AU2014352915B2 (en) 2018-03-15
ES2869172T3 (es) 2021-10-25
US10787449B2 (en) 2020-09-29
BR112016011826A2 (enExample) 2017-08-08
JP2024170470A (ja) 2024-12-10
DK3848027T3 (da) 2023-05-01
ZA201604026B (en) 2019-03-27
PH12016500968B1 (en) 2019-11-08
US20190135805A1 (en) 2019-05-09
EP3074011A4 (en) 2017-05-31
MY180141A (en) 2020-11-23
DK3074011T3 (da) 2019-09-30
US11560379B2 (en) 2023-01-24
KR102352737B1 (ko) 2022-01-17
US20250034140A1 (en) 2025-01-30
JP2021073315A (ja) 2021-05-13
CN106029066A (zh) 2016-10-12
CA2931302C (en) 2021-12-07
NZ720969A (en) 2021-05-28
PL3560493T3 (pl) 2021-10-04
PL3848027T3 (pl) 2023-07-24
MX2016006725A (es) 2016-09-09
US10323034B2 (en) 2019-06-18
JP6516743B2 (ja) 2019-05-22
US20230167111A1 (en) 2023-06-01
EP4219494A1 (en) 2023-08-02
US20150148341A1 (en) 2015-05-28
US20200361935A1 (en) 2020-11-19
EP3560493A1 (en) 2019-10-30
US10047082B2 (en) 2018-08-14
JP2019094355A (ja) 2019-06-20
AU2014352915A1 (en) 2016-06-30
ES2943542T3 (es) 2023-06-14
CN109761976A (zh) 2019-05-17
JP2023011052A (ja) 2023-01-20
MX368167B (es) 2019-09-23
US20190048004A1 (en) 2019-02-14
US11370789B2 (en) 2022-06-28
EP3848027A1 (en) 2021-07-14
KR20160089506A (ko) 2016-07-27
EP3074011B1 (en) 2019-07-24
RU2016123449A (ru) 2017-12-28
PT3074011T (pt) 2019-09-17
BR112016011826B1 (pt) 2022-09-27
PL3074011T3 (pl) 2020-01-31
FI3848027T3 (fi) 2023-05-04

Similar Documents

Publication Publication Date Title
CN109761976B (zh) 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
HK40002681A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
WO2015077537A1 (en) Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators
HK40056814B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40056814A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40002681B (zh) 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
HK40009157B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40009157A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK1228803A1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK1228803B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
NZ720969B2 (en) Octahydro fused azadecalin glucocorticoid receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002681

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant